Debiopharm expands its Immuno-Oncology development program for Debio 1143, with the first IAP inhibitor/nivolumab combination trial

Lausanne, Switzerland (ots) - First patient enrolled in
SMARTPLUS-106, a Phase lb/II study in patients failing prior
PD-1/PD-L1 treatment in selected solid tumors

Debiopharm (www.debiopharm.com) announced today the first patient
enrolled in SMARTPLUS-106, an exploratory study investigating the
safety and efficacy of Debio 1143, a first-in-class oral IAP
(Inhibitor of Apoptosis Proteins) inhibitor, in combination with the
Immune Checkpoint Inhibitor (ICI), nivolumab, in patients with
advanced solid tumors, such as small cell lung cancer (SCLC) or
squamous cell carcinoma of the head & neck (SCCHN), who have
progressed during or immediately after anti-PD-1/PD-L1 treatment.

Despite improved progression-free survival and overall survival
rates observed with ICIs in some patients, most either do not respond
to treatment or ultimately develop resistance to therapy, with only
10-30% of patients showing a durable treatment response.(1-3) The
combination of ICIs with Debio 1143 has strong therapeutic potential
through its dual mode of action, fostering anti-tumor immunity and
promoting programmed cell death in tumor cells.

Debio 1143 has demonstrated synergy with PD-1/PD-L1 ICIs,
including nivolumab, promoting tumor immunity in pre-clinical models
of cancer. Therefore the compound is expected to offer an
immune-sensitizing effect and enhance patient response to ICIs. With
SMARTPLUS-106, part of the broadest immune-oncology IAP clinical
research program, Debiopharm hopes to extend the reach of current
immunotherapy.

"As IAP inhibition has shown synergistic potential in combination
with immunotherapeutic agents, this study is of critical importance
to document the clinical efficacy of this new treatment combination
in patients not responding to ICIs." - Angela Zubel, Chief
Development Officer, Debiopharm International SA.

About Debio 1143

Debio 1143 is a IAPs inhibitor with a dual mode of action,
promoting programmed cell death and fostering anti-tumor immunity.
Currently in clinical development in a broad range of cancer types,
the compound is being tested combination with chemo-radiotherapy or
with ICIs (PD-1/PD-L1), with reported data consistently showing a
favorable and manageable safety profile. Over 200 patients have been
treated so far with Debio 1143, in indications such as non-small cell
lung cancer and Head & Neck cancer.

Trial information:

- Gastrointestinal cancers:
https://patients.debiopharm.com/gastrointestinal-cancers/

- Gynecologic cancers:
https://patients.debiopharm.com/gynecologic-cancer/

- Small cell lung cancers:
https://patients.debiopharm.com/small-cell-lung-cancer-sclc/

- Head & neck cancers:
https://patients.debiopharm.com/head-and-neck-cancer/

Debiopharm's commitment to cancer patients

Debiopharm aims to develop innovative therapies that target high
unmet medical needs in oncology. Bridging the gap between disruptive
discovery products and real-world patient reach, we identify
high-potential compounds for in-licensing, clinically demonstrate
their safety and efficacy and then select large pharmaceutical
commercialization partners to maximize patient access globally.

(1) Brahmer JR et al. J Clin Oncol. 2010;28(19):3167-75
(2) Antonia SJ et al. Lancet Oncol. 2016;17(7):883-95
(3) Ferris RL et al. Oral Oncol. 2018 Jun;81:45-51

Visit us www.debiopharm.com/

Follow us @DebiopharmNews at http://twitter.com/DebiopharmNews

Pressekontakt:
Debiopharm Contact
Dawn Haughton - Communication Manager
dawn.haughton@debiopharm.com
Tel: +41 (0)21 321 01 11

Original-Content von: Debiopharm International SA, übermittelt durch news aktuell